Phathom Pharmaceuticals, Inc. Stock Price, News & Analysis

Phathom Pharmaceuticals (NASDAQ: PHAT) has issued a clarification regarding a Schedule 13D filing by Frazier Life Sciences. The company emphasized that the upcoming filing includes only administrative changes to the reporting approach and does not represent any reduction in Frazier's ownership position in Phathom.

While the updated filing may show different breakouts of holdings between funds and persons, and changes in warrant treatment may affect certain percentage calculations, these modifications are purely administrative in nature. The company confirms that no actual sale of shares has occurred.

Phathom Pharmaceuticals (NASDAQ:PHAT) reported strong Q2 2025 financial results, with net revenues of $39.5 million, up significantly from $7.3 million in Q2 2024. The company's VOQUEZNA® products reached over 580,000 filled prescriptions, showing 49% growth since the last earnings report. Commercial coverage remains robust with access to over 120 million lives.

The company provided full-year 2025 revenue guidance of $165-175 million and expects to achieve profitability in 2026. Q2 net loss was $75.8 million, improved from $91.4 million in Q2 2024. Cash position stands at $149.6 million as of June 30, 2025. The FDA has updated VOQUEZNA's exclusivity through May 2032, with generic entry unlikely before 2033.

Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal disease treatments, will host a webcast on August 7, 2025, at 8:00 am EDT to discuss Q2 2025 financial results and provide a business update.

The company markets VOQUEZNA® (vonoprazan) tablets in the US for heartburn relief and GERD treatment, along with VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment. The webcast will be accessible through Phathom's investor relations website, with a recording available for 90 days following the event.

Phathom Pharmaceuticals (NASDAQ: PHAT) announced the approval of inducement awards for their newly appointed Chief Legal Officer and Corporate Secretary, Anne Marie Cook. The compensation package includes a non-qualified stock option to purchase 210,000 shares of Phathom common stock, with 25% vesting on June 23, 2026, and the remainder vesting in 36 monthly installments. Additionally, Cook received 50,400 performance stock units with potential earnings up to 200% of target, tied to company financial objectives through December 31, 2027.

The awards are granted under the company's 2025 Employment Inducement Incentive Award Plan and comply with Nasdaq Listing Rule 5635(c)(4). Phathom specializes in developing treatments for gastrointestinal diseases and markets VOQUEZNA® in the United States.

Phathom Pharmaceuticals (NASDAQ: PHAT) has appointed Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Cook brings extensive pharmaceutical legal experience, having previously served as Senior Vice President and General Counsel at Sage Therapeutics, with prior legal leadership positions at Aegerion, ViaCell, and Biogen. Her expertise spans corporate governance, commercial law, regulatory compliance, strategic transactions, and legal strategy. CEO Steven Basta emphasized Cook's potential impact on building Phathom into a leading GI company. Cook expressed enthusiasm about joining Phathom during its commercial evolution phase, highlighting the company's potential to transform acid-related GI disease treatment standards.

Phathom Pharmaceuticals (NASDAQ: PHAT) announced that the FDA has corrected the Orange Book listing for VOQUEZNA® (vonoprazan) tablets, confirming its 10-year New Chemical Entity (NCE) exclusivity period through May 3, 2032. VOQUEZNA, a first-in-class potassium-competitive acid blocker (PCAB), is approved for treating heartburn associated with Non-Erosive GERD and Erosive GERD in adults. The product is also available as VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori infection treatment. This correction reinforces the long-term commercial potential for this novel GI treatment, ensuring market protection for the full statutory period.

Phathom Pharmaceuticals (NASDAQ: PHAT) announced that the FDA has approved their Citizen Petition and will extend regulatory exclusivity for VOQUEZNA (vonoprazan) tablets through May 3, 2032. This grants the company 10 years of New Chemical Entity exclusivity for their first-in-class potassium-competitive acid blocker (PCAB). VOQUEZNA is currently marketed in the US for treating heartburn associated with Non-Erosive GERD in adults, healing and maintenance of Erosive GERD, and as VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori infection treatment. This FDA decision strengthens Phathom's market position by protecting their intellectual property rights for an extended period.

Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal disease treatments, has announced its participation in three upcoming investor conferences:

1. H.C. Wainwright BioConnect Investor Conference on May 20, 2025, at 4:00 p.m. ET in New York

2. Jefferies Global Healthcare Conference on June 5, 2025, at 9:55 a.m. ET in New York

3. Goldman Sachs Global Healthcare Conference on June 11, 2025, at 10:40 a.m. ET in Miami Beach

The company will conduct one-on-one meetings at all events. Live webcasts and 90-day archived recordings will be available on Phathom's investor relations website.

Phathom Pharmaceuticals (NASDAQ: PHAT) announced the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, along with associated inducement awards. The Board granted Bentley a non-qualified stock option to purchase 79,365 shares of common stock, with 25% vesting on May 1, 2026, and the remainder vesting in 36 monthly installments. Additionally, Bentley received 57,143 restricted stock units vesting in three equal annual installments and 50,000 restricted stock units vesting in two equal annual installments.

Phathom specializes in gastrointestinal disease treatments and markets VOQUEZNA® for heartburn and GERD treatment, along with VOQUEZNA® TRIPLE PAK® and DUAL PAK® for H. pylori infection treatment.